Anti-MAG Antibody Neuropathy Treated Successfully with Pomalidomide and Dexamethasone: A Case Report
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Anti-myelin-associated glycoprotein (MAG) neuropathy is a rare, immune-mediated demyelinating condition.It is characterised by an association with an IgM monoclonal gammopathy and the presence of pathogenic anti-MAG antibodies.Research into this field began in the 1980s.Initial therapeutic approaches aimed to reduce the M protein concentration using treatments such as plasma exchange, steroids, chlorambucil, azathioprine and cyclophosphamide.Some patients experienced partial benefit, indicating that mechanisms beyond damage solely caused by elevated M protein are involved.Consequently, immune-directed therapies, such as IVIg and rituximab, have demonstrated some efficacy in this patient group.Some case reports suggested the use of Lenalidomide as a potential therapeutic option.This is the first case report showing the successful use of pomalidomide in anti-MAG neuropathy.
Fields of Study & Subjects
Peripheral Neuropathies and Disorders
Autoimmune Neurological Disorders and Treatments
Multiple Sclerosis Research Studies
Publication details
- Journal / source
- Journal of Medicine and Medical Studies
- Volume
- 3
- Issue
- 1
- Pages
- 267–269
- Publication date
- 31 March 2026
- Language
- EN